No Detail Found!

Clinical Outcomes in type 2 diabetics switched to Insulin Degludec As part from conventional Premixed Insulin therapy

Author(s)
Komal Mumtaz Malik Department of Pharmacology, Army Medical College, National University of Medical Sciences, Pak Emirates Military Hospital,Rawalpindi,Pakistan
Kulsoom Farhat Department of Pharmacology, Army Medical College, National University of Medical Sciences, Pak Emirates Military Hospital,Rawalpindi,Pakistan
Muhammad Asghar Khan Department of Pharmacology, Army Medical College, National University of Medical Sciences, Pak Emirates Military Hospital,Rawalpindi,Pakistan
Bilal Ahmad Department of Pharmacology, Army Medical College, National University of Medical Sciences, Pak Emirates Military Hospital,Rawalpindi,Pakistan
Shabana Ali Department of Pharmacology, Army Medical College, National University of Medical Sciences, Pak Emirates Military Hospital,Rawalpindi,Pakistan
Mudassar Noor Department of Pharmacology, Army Medical College, National University of Medical Sciences, Pak Emirates Military Hospital,Rawalpindi,Pakistan
Abstract
Objective: To compare the glycemic control of a newer insulin co-formulation, insulin degludec as part with the conventional premixed insulin therapy, in type 2 diabetes mellitus. Methodology: We included 120 participants with documented type 2 diabetes, taking premixed insulin therapy. They were divided into two groups; Group B participants were switched to once-daily insulin degludec as part whereas those in group A continued receiving biphasic insulin as part. Glycemic control was assessed with Hemoglobin A1c levels, fasting, and post-prandial plasma glucose concentrations of the participants during a 12-week study period. Results: HbA1c, Fasting and 2-hour post prandial plasma glucose concentrations were significantly reduced in participants taking insulin degludec as part (p<0.05). Conclusion: Use of degludec as part has simplified dosage method, increased treatment compliance, and produced better clinical outcomes in Pakistani population.
Publication Details
Page(s) 805-808
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 48, Issue: 4, Year: 2023

Request the full text from PASTIC

Keywords
Glycemic control, Type 2 diabetes mellitus., insulin degludec as part, Biphasic insulin as part
References
Jawed K,Nisar N,Hussain M,Nawab F M .2019 .A study based on use of Complementary and Alternative Medicine among Diabetic Patients in Karachi, Pakistan. J Dow Univ Health Sci, : 1310-6.
Basit A,Fawwad A,Abdul Basit K,Waris N,Tahir B,Siddiqui IA .2020 .Glycated hemoglobin (HbA1c) as diagnostic criteria for diabetes: the optimal cut-off points values for the Pakistani population; a study from second National Diabetes Survey of Pakistan (NDSP). BMJ Open Diabetes Res Care, 8 : 1058.
Almetwazi M,Alwhaibi M,Balkhi B,Almohaini H,Alturki H,Alhawassi T .2019 .Factors associated with glycemic control in type 2 diabetic patients in Saudi Arabia. Saudi Pharm J, 27 : 384-8.
Dharmeshkumar DP,Patel NM,Savadi RV,Akki KS .2008 .Mruthunjaya K. Alleviation of alloxan-induced diabetes and its complications in rats by Actinodaphnehookeri leaf extract. Bangladesh J. Pharmacol, 3 : 102-6.
Garber AJ,Abrahamson MJ,Barzilay JI,Blonde L,Bloomgarden ZT,Bush MA .2016 .Consensus Statement by The American Association of Clinical Endocrinologists and American College of Endocrinology on The Comprehensive Type 2 Diabetes Management Algorithm--2016 Executive Summary. Endocr Pract, 22 : 84-113.
Mehmood R,Khan M,Jawed I,Mahmood I .2011 .Comparison of Efficacy and Safety Profile of Gabapentin and Carbamazepine in Painful Diabetic Neuropathy. J Dow Univ Health Sci, 5 : 55-9.
Kalra S,Atkin S,Cervera A,Das AK,Demir O. Multinational AK .2018 .Consensus: Insulin Initiation with Insulin Degludec/As part (IDegAsp). Adv Ther, 35 : 928-36.
Hanefeld M,Fleischmann H,Siegmund T,Seufert J .2020 .Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020. Update. Diabetes Ther, 11 : 1645-66.
Cho KY,Nakamura A,Oba-Yamamoto C,Tsuchida K,Yanagiya S K .2020 .Switching to Once Daily Insulin Degludec/ Insulin As part from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial. Diabetes Metab J, 44 : 532-41.
Mehta R,Chen R,Hirose T,John M,Kok A .2020 .Practical use of insulin degludec/insulin as part in a multinational setting: beyond the guidelines. Diabetes Obes Metab, 22 : 1961-75.
Haahr H,Fita EG,T. EG .2017 .A Review of Insulin Degludec/Insulin As part: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use. Clin Pharmacokinet, 56 : 339-54.
Hirose T,Awata T,Yamamoto Y,Hemmingsen MP. .2018 .Clinical considerations for use of insulin degludec/insulin as part in Japanese patients. Expert Opin Biol Ther, 18 : 77-85.
Özçelik S,Çelik M,Vural A,Aydın B,Özçelik M. .2020 .Outcomes of transition from premixed and intensive insulin therapies to insulin as part/degludec coformulation in type 2 diabetes mellitus: a real-world experience. Arch Med Sci, 17 : 1-8.
Yang W,Ma J,Hong T.,Efficacy T. .2019 .and safety of insulin degludec/insulin as part versus biphasic insulin as part 30 in Chinese adults with type 2 diabetes: A phase III, openlabel, 2:1 randomized, treat-to-target trial. Diabetes Obes Metab, 21 : 1652-60.
Demir T,Turan S,Unluhizarci K,Topaloglu O,Tukek T .2021 .Use of Insulin Degludec/Insulin As part in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns. Front Endocrinol, 12 : 616514.
Moon S,Chung HS,Kim Y,Yu JM,Jeong WJ JM .2021 .Efficacy and Safety of Insulin Degludec/Insulin As part Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis. Metabolites, 11 : 639.
0

Citations

0

Downloads

45

Views